Biohaven initiates second pivotal Phase 3 clinical trial of rimegepant
Biohaven Pharmaceutical announced that it has commenced enrollment in the second of its two registrational Phase 3 clinical trials to evaluate the safety and efficacy of its orally-dosed rimegepant for the acute treatment of migraine. Biohaven is conducting two double-blinded, placebo-controlled Phase 3 clinical trials to evaluate the efficacy and safety of 75 mg of rimegepant, Biohaven's innovative, orally-dosed small molecule CGRP receptor antagonist, for the acute treatment of migraine. The co-primary endpoints of the studies are freedom from pain at two hours post-dosing and a demonstrated effect on the patient's most bothersome symptom at two hours post-dosing. Patients in the Phase 3 clinical trials will be eligible to participate in a long-term safety study.